Expertise in
13
conditions

Dr. Joyce M. Teng

Pediatrics
Lucile Packard Children's Hospital Stanford
725 Welch Rd, 
Palo Alto, CA 
Accepting New Patients
Offers Telehealth
Expertise in
13
conditions
Lucile Packard Children's Hospital Stanford
725 Welch Rd, 
Palo Alto, CA 

Overview

Joyce Teng is a Pediatrics provider practicing medicine in Palo Alto, California.

Dr. Teng is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Aplasia Cutis Congenita, Vascular Birthmark, Arteriovenous Malformation, Congenital Athymia, and Liver Embolization.

She is actively involved in clinical research, co-authoring 120 peer reviewed articles and participating in 11 clinical trials. Dr. Teng is currently accepting new patients.

Specialties

Pediatrics

Licenses

Dermatology in CA

Hospital Affiliations

Lucile Salter Packard Children's Hsp At Stanford

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Contra Costa Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Health Plan of San Mateo
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Highmark
  • EPO
  • HMO
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Valley Health
  • HMO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 17 Less Insurance Carriers -

Locations

Lucile Packard Children's Hospital Stanford
725 Welch Rd, Palo Alto, CA 94304
Other Locations
Lucille Packard Children's Hospital 030962
770 Welch Rd, Palo Alto, CA 94304

Additional Areas of Focus

Dr. Teng has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase II Clinical Trial of MEK Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation (VM)
Phase II Clinical Trial of MEK Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation (VM)
Enrollment Status: Completed
Publish Date: April 24, 2026
Intervention Type: Drug
Study Phase: Phase 2
Managed Access Programs for BYL719, Alpelisib
Managed Access Programs for BYL719, Alpelisib
Enrollment Status: Available
Publish Date: April 14, 2026
Intervention Type: Drug
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: QTORIN rapamycin anhydrous gel
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase I/II, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
A Phase I/II, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
Enrollment Status: Completed
Publish Date: September 11, 2023
Intervention Type: Drug
Study Drug: TolaSure
Study Phase: Phase 1
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Drug, Other
Study Drug: Sildenafil
Study Phase: Phase 2
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Enrollment Status: Terminated
Publish Date: August 04, 2022
Intervention Type: Drug
Study Drug: VT30
Study Phase: Phase 1/Phase 2
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Drug
Study Drugs: Sirolimus, Vehicle
Study Phase: Phase 2
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

120 Total Publications

Subclonal IDH1/2 Mutations as a Targetable Vulnerability in Vascular Tumors.
Subclonal IDH1/2 Mutations as a Targetable Vulnerability in Vascular Tumors.
Journal: bioRxiv : the preprint server for biology
Published: May 25, 2026
Similar Doctors
Expertise in
121
conditions
Dr. Yang D. Liu
Pediatrics
Expertise in
121
conditions
Dr. Yang D. Liu
Pediatrics
Referral may be required

Kaiser Health Plan Family PHY 635

276 Hospital Pkwy, 
San Jose, CA 
 (24.7 miles away)
408-362-4740
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Yang Liu is a Pediatrics provider practicing medicine in San Jose, California. Dr. Liu is highly rated in 121 conditions, according to our data. His clinical expertise encompasses Cerebral Hypoxia, Gliomatosis Cerebri, Acute Pain, Endoscopy, and Lithotripsy. Dr. Liu is currently accepting new patients.

Expertise in
13
conditions
Dr. David K. Stevenson
Neonatology | Pediatrics
Expertise in
13
conditions
Dr. David K. Stevenson
Neonatology | Pediatrics
Referral may be required

Lucile Packard Children's Hospital Stanford

725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

David Stevenson is a Neonatologist and a Pediatrics provider practicing medicine in Palo Alto, California. Dr. Stevenson is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Transient Familial Hyperbilirubinemia, Newborn Jaundice, Bilirubin Encephalopathy, and Jaundice.

Expertise in
100
conditions
Dr. David A. Stevenson
Medical Genetics | Pediatrics
Expertise in
100
conditions
Dr. David A. Stevenson
Medical Genetics | Pediatrics
Referral may be required

Lpch Medical Group Div Of Lucile

725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
650-498-7200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Stevenson is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Palo Alto, California. Dr. Stevenson is highly rated in 100 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis Type 1 (NF1), Neurofibromatosis, RASopathies, Costello Syndrome, and Deep Brain Stimulation.

Frequently Asked Questions about Dr. Joyce M. Teng

How do I make an appointment with Dr. Joyce M. Teng?

You can book an appointment with Dr. Joyce M. Teng by calling their office at 650-497-8000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joyce M. Teng a top-rated expert for Aplasia Cutis Congenita?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joyce M. Teng is classified as an Distinguished expert for Aplasia Cutis Congenita, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joyce M. Teng specialize in?

While Dr. Joyce M. Teng is a Pediatrics, they have specific expertise in Aplasia Cutis Congenita, Vascular Birthmark, and Arteriovenous Malformation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Joyce M. Teng participate in research or clinical trials?

Yes. Dr. Joyce M. Teng has published 120 articles and abstracts on conditions like Aplasia Cutis Congenita. You can view a list of Dr. Joyce M. Teng's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joyce M. Teng accept my insurance?

Dr. Joyce M. Teng accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 650-497-8000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Teng's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile